Rayyan Therapeutics is developing a next generation thrombolytic for ischemic stroke. Our engineered, protease resistant enzyme targets clot formation at its source and protects microcirculation, with the goal of extending the safe treatment window so more patients qualify for therapy.
Founders
Hasam Madarati
Founder
Featured Stories
The Forge Welcomes Final Business Incubator Cohort of 2025
The Forge, McMaster University’s startup incubator, is proud to announce the launch of its final Business Incubator cohort of 2025,...